Skip to main content
Journal cover image

Baseline neurocognitive deficits in the CATIE schizophrenia trial.

Publication ,  Journal Article
Keefe, RSE; Bilder, RM; Harvey, PD; Davis, SM; Palmer, BW; Gold, JM; Meltzer, HY; Green, MF; Miller, DD; Canive, JM; Adler, LW; Manschreck, TC ...
Published in: Neuropsychopharmacology
September 2006

Neurocognition is moderately to severely impaired in patients with schizophrenia. However, the factor structure of the various neurocognitive deficits, the relationship with symptoms and other variables, and the minimum amount of testing required to determine an adequate composite score has not been determined in typical patients with schizophrenia. An 'all-comer' approach to cognition is needed, as provided by the baseline assessment of an unprecedented number of patients in the CATIE (Clinical Antipsychotic Trials of Intervention Effectiveness) schizophrenia trial. From academic sites and treatment providers representative of the community, 1493 patients with chronic schizophrenia were entered into the study, including those with medical comorbidity and substance abuse. Eleven neurocognitive tests were administered, resulting in 24 individual scores reduced to nine neurocognitive outcome measures, five domain scores and a composite score. Despite minimal screening procedures, 91.2% of patients provided meaningful neurocognitive data. Exploratory principal components analysis yielded one factor accounting for 45% of the test variance. Confirmatory factor analysis showed that a single-factor model comprised of five domain scores was the best fit. The correlations among the factors were medium to high, and scores on individual factors were very highly correlated with the single composite score. Neurocognitive deficits were modestly correlated with negative symptom severity (r=0.13-0.27), but correlations with positive symptom severity were near zero (r<0.08). Even in an 'all-comer' clinical trial, neurocognitive deficits can be assessed in the overwhelming majority of patients, and the severity of impairment is similar to meta-analytic estimates. Multiple analyses suggested that a broad cognitive deficit characterizes this sample. These deficits are modestly related to negative symptoms and essentially independent of positive symptom severity.

Duke Scholars

Published In

Neuropsychopharmacology

DOI

ISSN

0893-133X

Publication Date

September 2006

Volume

31

Issue

9

Start / End Page

2033 / 2046

Location

England

Related Subject Headings

  • Schizophrenic Psychology
  • Psychomotor Performance
  • Psychiatry
  • Neuropsychological Tests
  • Memory
  • Male
  • Humans
  • Female
  • Data Interpretation, Statistical
  • Cognition Disorders
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Keefe, R. S. E., Bilder, R. M., Harvey, P. D., Davis, S. M., Palmer, B. W., Gold, J. M., … Lieberman, J. A. (2006). Baseline neurocognitive deficits in the CATIE schizophrenia trial. Neuropsychopharmacology, 31(9), 2033–2046. https://doi.org/10.1038/sj.npp.1301072
Keefe, Richard S. E., Robert M. Bilder, Philip D. Harvey, Sonia M. Davis, Barton W. Palmer, James M. Gold, Herbert Y. Meltzer, et al. “Baseline neurocognitive deficits in the CATIE schizophrenia trial.Neuropsychopharmacology 31, no. 9 (September 2006): 2033–46. https://doi.org/10.1038/sj.npp.1301072.
Keefe RSE, Bilder RM, Harvey PD, Davis SM, Palmer BW, Gold JM, et al. Baseline neurocognitive deficits in the CATIE schizophrenia trial. Neuropsychopharmacology. 2006 Sep;31(9):2033–46.
Keefe, Richard S. E., et al. “Baseline neurocognitive deficits in the CATIE schizophrenia trial.Neuropsychopharmacology, vol. 31, no. 9, Sept. 2006, pp. 2033–46. Pubmed, doi:10.1038/sj.npp.1301072.
Keefe RSE, Bilder RM, Harvey PD, Davis SM, Palmer BW, Gold JM, Meltzer HY, Green MF, Miller DD, Canive JM, Adler LW, Manschreck TC, Swartz M, Rosenheck R, Perkins DO, Walker TM, Stroup TS, McEvoy JP, Lieberman JA. Baseline neurocognitive deficits in the CATIE schizophrenia trial. Neuropsychopharmacology. 2006 Sep;31(9):2033–2046.
Journal cover image

Published In

Neuropsychopharmacology

DOI

ISSN

0893-133X

Publication Date

September 2006

Volume

31

Issue

9

Start / End Page

2033 / 2046

Location

England

Related Subject Headings

  • Schizophrenic Psychology
  • Psychomotor Performance
  • Psychiatry
  • Neuropsychological Tests
  • Memory
  • Male
  • Humans
  • Female
  • Data Interpretation, Statistical
  • Cognition Disorders